← Back to RNS Announcements
ANNUAL FINANCIAL REPORT ANNOUNCEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31 AUGUST 2016
After a number of years of strong growth, returns for the Company were lower in the year ended 31 August 2016 with the NAV per share down 1.7%. This reflected a period of consolidation in the biotechnology sector. Although 2016 was a challenging year for the biotechnology market, our Investment Manager has outperformed the NBI for the second consecutive year.
Published on 4th November 2016